Biophan: Hoffen auf den Rebreak - 500 Beiträge pro Seite

[4investors]

Charttechnische Analyse mit Handlungsoptionen.

Am Montag hat die Aktie ein negatives Chartsignal generiert, das einiges Abwärtspotenzial freisetzt: Der Titel hat den Support bei 1,01 Dollar unterschritten. Zuvor ist die Aktie nicht mehr über die ehemalige Unterstützung bei 1,09 Dollar hinweggekommen. Durch den Break der unteren Support-Linie befindet sich die Aktie im „luftleeren“ Raum: Erst bei 0,61 Dollar liegt der nächste Support: Zwischen 0,55 und 0,61 Dollar liegt eine Unterstützungszone, die durch ein Rising Window zu Jahresbeginn entstanden ist.

Der Break ist grenzwertig hinsichtlich der Signifikanz. Im Tagesverlauf hat die Aktie einen Teil des verlorenen Bodens zurück erobern können. Unter dem Strich verbleibt ein Unterschreiten der Linie von gut drei Prozent. Wird der Break bestätigt, wäre ein bearishes Dreieck aufgelöst, das sich seit Jahresanfang herausgebildet hat. Theoretisch ergibt sich daraus ein Abwärtspotenzial bis auf 0,35 Dollar, doch als primäres Ziel sollte der Support-Bereich zwischen 0,55 und 0,65 Dollar angesehen werden.

Die technischen Indikatoren sind überwiegend neutral ausgerichtet, selbst der relativ schnell reagierende Stochastics (Slow) ist noch nicht im überverkauften Bereich eingetroffen. Trotzdem gehören bei fallenden Dreiecken Rückkehrbewegungen zu gewohnten Bild. Hierauf ruhen die Hoffnungen, dass die Aktie relativ rasch den Rebreak vollzieht und die gefährliche Lage klärt. Sollte jedoch der Kurs jedoch bei 1,01 Dollar scheitern, wäre die Zeit für Short-Positionen gekommen. Bestehende Aktienpositionen sollten aus Gründen der Risiko-Minimierung geschlossen werden.

Chart erstellt mit TradeSignal express, www.tradesignal.com


Autor: 4investors.de (© 4investors.de),08:03 11.05.2004

[aida74]

mamma mia, das sind ja TRAUMHAFTE Umsätze:

Börse Symbol Währ. Vortag akt.Kurs Diff. % Handelsvol. gehand. St. Kurszeit
München BTN EUR 0,890 0,880 - 0,010 - 1,12 % 0 7.610 25. Mai 09:04
Frankfurt BTN EUR 0,890 0,870 - 0,020 - 2,25 % 1.044 1.200 25. Mai 09:05
Berlin BTN EUR 0,850 0,830 - 0,020 - 2,35 % 0 0 25. Mai 09:10
OTCBB BIPH USD 1,08 1,04 - 0,045 - 4,17 % 381.149 374.372 24. Mai 21:59
Xetra BTN EUR 0,900 0,880 - 0,020 - 2,22 % 0 0 20. Mai 13:2

[asskicker]

(BSNS WIRE) Comprehensive Report on Biophan Technologies Published by Cohen I
dependent Research Group
Comprehensive Report on Biophan Technologies Published by Cohen Independent Rese
rch Group


Health/Medical Writers / Business Editors

ROCHESTER, N.Y.--(BUSINESS WIRE)--BIPH--


Highly Detailed Report Provides Institutional-Quality Analysis to
Assist Retail Investors

Biophan Technologies, Inc. (OTCBB:BIPH), a leading developer of
next generation biomedical technology, announced today that a
comprehensive analytical report on the Company has been published by
Cohen Independent Research Group and is available for viewing and/or
download for all interested parties. The report provides extensive
details about the Company, its recent acquisition, and its vision for
the future. Interested parties can access the report at
www.biophan.com/reports/BIPH_052404.pdf.
The highly detailed fifty-five page report, which was paid for by
the company, provides three potential scenarios: pessimistic, base,
and optimistic with proforma share price targets of $4.46, $7.80, and
$10.59.
Michael Weiner, CEO of Biophan, remarked, "In our unwavering
commitment to maximum disclosure and transparency, we are pleased to
have this report readily available for all our current and potential
investors. With all the scrutiny that equity research has come under
in recent years, we like the fact that Cohen Independent Research
Group has generated such a highly detailed, institutional-quality
report on the Company."
D. Paul Cohen, president of Cohen Independent Research Group,
noted, "Although we were engaged by the Company to publish this
report, we take great pride in maintaining our independence and to
offer a fair and balanced view. We believe today`s investors are
highly sophisticated. As a result, it is our objective to present
significant data using multiple valuation models, and to let the
investors reach the appropriate buy, sell or hold conclusions."

About Cohen Independent Research Group

Cohen Independent Research Group provides Wall Street
Research-Analyst Coverage for selected companies with outstanding
business models. These companies have no Wall Street Research-Analyst
Coverage, or have minimal analyst coverage. Individual companies and
institutional money managers comprise the client list of Cohen
Independent Research Group. More than 20 of the top 100 institutions
in the USA are on the firm`s client list, as are many public
corporations. Cohen Independent Research Group is also hired by
institutional investors to do special project, fundamental,
investigative, and accounting research. The firm is considered by many
to be the leading independent research firm in the USA.
www.cohenresearch.com.

About Biophan Technologies

Biophan Technologies develops and markets cutting-edge
technologies designed to make biomedical devices--such as cardiac
pacemakers, surgical and diagnostic tools--safe and compatible with
magnetic resonance imaging (MRI) equipment. The Company develops
enabling technologies for implanted medical systems such as
pacemakers, and interventional surgical devices such as catheters and
guidewires, as well as stents and other implants that can be safely
and effectively imaged under MRI. The technology is also being used to
create enhanced MRI contrast agents. Committed to growth through
innovation and developmental leadership, Biophan and its licensors
have nine issued U.S. patents and over fifty patents pending, in areas
including nanotechnology (nanomagnetic particle coatings), radio
frequency filters, polymer composites, and photonics. Biophan`s
technology will help realize its goal of one day making all biomedical
devices capable of safely and successfully working with MRI. For more
information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements and
Disclaimer

Certain statements included in this press release may constitute
forward-looking statements. Actual results could differ materially
from such statements expressed or implied herein as a result of a
variety of factors including, but not limited to: the development of
Biophan`s MRI technologies; the approval of Biophan`s patent
applications; the successful implementation of Biophan`s research and
development programs; the acceptance by the market of Biophan`s
products; competition and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to
time in Biophan`s periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read
in conjunction with Biophan`s periodic filings with the SEC. The
forward-looking statements contained herein are made only as of the
date of this press release, and Biophan undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent
events or circumstances. In addition, the company paid for the Cohen
Independent Research Group report discussed in this release. The
compensation was $25,000 in cash.



KEYWORD: INTERNATIONAL EUROPE NEW YORK
INDUSTRY KEYWORD: BANKING MEDICAL MEDICAL MEDICAL DEVICES MEDICAL BIOTECHNOLOGY
SOURCE: Biophan Technologies, Inc.


CONTACT INFORMATION:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Michael Weiner, 585-214-2441

*** end of story ***